All In Biotech

NDA 021877 · Sandoz

Arranon

Nelarabine · Intravenous · Nucleoside Metabolic Inhibitor

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Oct 28, 2005

Approved uses

2

Original approval plus efficacy supplements

Registered trials

31

6 Phase 3, 3 recruiting

FAERS reports

974

937 serious, 213 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEUROLOGIC ADVERSE REACTIONS Severe neurologic adverse reactions have been reported with the use of ARRANON ® . These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination, and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome [see Warnings and Precautions (5.1)]. Full recovery from these adverse reactions has not always occurred with cessation of therapy with ARRANON. Monitor frequently for signs and symptoms of neurologic toxicity during treatment with ARRANON. Discontinue ARRANON for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or...

What it is approved for

From the label in effect Mar 31, 2025.

ARRANON is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. ARRANON is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. ( 1 )

Mechanism: Nelarabine is a prodrug of the deoxyguanosine analogue 9-β- D -arabinofuranosylguanine (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by ADA to ara-G, mono-phosphorylated by deoxyguanosine kinase and deoxycytidine kinase, and subsequently converted to the active 5’-triphosphate, ara-GTP. Accumulation of ara-GTP in leukemic blasts allows for incorporation into deoxyribonucleic acid (DNA), leading to inhibition of DNA synthesis and cell death. Other mechanisms may contribute to the cytotoxic and systemic toxicity of nelarabine.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 2019 Supplement 10 · Efficacy OrphanLetterLabel
  • Oct 28, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
1 products under this application
  • ARRANON · NELARABINE 250MG/50ML (5MG/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Nelarabine" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia76
  • drug ineffective67
  • neuropathy peripheral63
  • neurotoxicity61
  • peripheral sensory neuropathy56
  • sepsis56
  • muscular weakness55
  • off label use53
  • myelopathy52
  • neutropenia52
  • guillain-barre syndrome42
  • thrombocytopenia41

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200610
200713
200817
200924
201026
201126
201227
201373
201452
201539
201648
201764
201856
201929
202039
202135
202298
202377
202468
2025116
202637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Arranon* (Nelarabine*) · HCPCS J9261

2024 spending

$89K

Beneficiaries

n/a

30 claims

Per beneficiary

n/a

2024 ASP limit $89.69 per unit

View as table
YearSpending
2020$541,497
2021$563,199
2022$403,824
2023$374,025
2024$89,435

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 30 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.